BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23936194)

  • 21. Theoretical Analysis of Activity Cliffs among Benzofuranone-Class Pim1 Inhibitors Using the Fragment Molecular Orbital Method with Molecular Mechanics Poisson-Boltzmann Surface Area (FMO+MM-PBSA) Approach.
    Watanabe C; Watanabe H; Fukuzawa K; Parker LJ; Okiyama Y; Yuki H; Yokoyama S; Nakano H; Tanaka S; Honma T
    J Chem Inf Model; 2017 Dec; 57(12):2996-3010. PubMed ID: 29111719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
    Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
    Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of substituted pyrido[3,2-d]-1,2,3-triazines as potential Pim-1 inhibitors.
    Fan YB; Li K; Huang M; Cao Y; Li Y; Jin SY; Liu WB; Wen JC; Liu D; Zhao LX
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1224-8. PubMed ID: 26804231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIM1 kinase as a target for cancer therapy.
    Merkel AL; Meggers E; Ocker M
    Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.
    Wissing J; Godl K; Brehmer D; Blencke S; Weber M; Habenberger P; Stein-Gerlach M; Missio A; Cotten M; Müller S; Daub H
    Mol Cell Proteomics; 2004 Dec; 3(12):1181-93. PubMed ID: 15475568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
    Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.
    Quevedo CE; Bataille CJR; Byrne S; Durbin M; Elkins J; Guillermo A; Jones AM; Knapp S; Nadali A; Walker RG; Wilkinson IVL; Wynne GM; Davies SG; Russell AJ
    Bioorg Med Chem; 2020 Nov; 28(22):115724. PubMed ID: 33128909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using insights into Pim1 structure to design new anticancer drugs.
    Schenone S; Tintori C; Botta M
    Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of pyrrolo[2,3-g]indazoles as new Pim kinase inhibitors.
    Gavara L; Suchaud V; Nauton L; Théry V; Anizon F; Moreau P
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2298-301. PubMed ID: 23499503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
    Holder SL; Abdulkadir SA
    Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
    Liu Y; Agrawal NJ; Radhakrishnan R
    J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.
    Sliman F; Blairvacq M; Durieu E; Meijer L; Rodrigo J; Desmaële D
    Bioorg Med Chem Lett; 2010 May; 20(9):2801-5. PubMed ID: 20363627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.
    Sarno S; Mazzorana M; Traynor R; Ruzzene M; Cozza G; Pagano MA; Meggio F; Zagotto G; Battistutta R; Pinna LA
    Cell Mol Life Sci; 2012 Feb; 69(3):449-60. PubMed ID: 21720886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
    Bullock AN; Russo S; Amos A; Pagano N; Bregman H; Debreczeni JE; Lee WH; von Delft F; Meggers E; Knapp S
    PLoS One; 2009 Oct; 4(10):e7112. PubMed ID: 19841674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolutionary variation and adaptation in a conserved protein kinase allosteric network: implications for inhibitor design.
    Oruganty K; Kannan N
    Biochim Biophys Acta; 2013 Jul; 1834(7):1322-9. PubMed ID: 23499783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruthenium half-sandwich complexes bound to protein kinase Pim-1.
    Debreczeni JE; Bullock AN; Atilla GE; Williams DS; Bregman H; Knapp S; Meggers E
    Angew Chem Int Ed Engl; 2006 Feb; 45(10):1580-5. PubMed ID: 16381041
    [No Abstract]   [Full Text] [Related]  

  • 38. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.
    Nguyen D; Lemos C; Wortmann L; Eis K; Holton SJ; Boemer U; Moosmayer D; Eberspaecher U; Weiske J; Lechner C; Prechtl S; Suelzle D; Siegel F; Prinz F; Lesche R; Nicke B; Nowak-Reppel K; Himmel H; Mumberg D; von Nussbaum F; Nising CF; Bauser M; Haegebarth A
    J Med Chem; 2019 Jan; 62(2):928-940. PubMed ID: 30563338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure guided design of potential inhibitors of human calcium-calmodulin dependent protein kinase IV containing pyrimidine scaffold.
    Naz H; Jameel E; Hoda N; Shandilya A; Khan P; Islam A; Ahmad F; Jayaram B; Hassan MI
    Bioorg Med Chem Lett; 2016 Feb; 26(3):782-788. PubMed ID: 26783179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
    Nafie MS; Amer AM; Mohamed AK; Tantawy ES
    Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.